Advanced search
Publication Cover
Cancer Biology & Therapy Volume 20, 2019 - Issue 8
Submit an article Journal homepage
969
Views
3
CrossRef citations to date
0
Altmetric
Bedside-to-Bench Report

NUT midline carcinoma in the right orbit: a case report

Tingting DingDepartment of Oncology, Shanghai Yangpu District Shidong Hospital, Shanghai, P.R.China
,
Yajin WangDepartment of Oncology, Shanghai Yangpu District Shidong Hospital, Shanghai, P.R.China
,
Tai ZhaoDepartment of Oncology, Shanghai Yangpu District Shidong Hospital, Shanghai, P.R.China
,
Zhoumin XuDepartment of Oncology, Shanghai Yangpu District Shidong Hospital, Shanghai, P.R.China
,
Wenwen GaoDepartment of Oncology, Shanghai Yangpu District Shidong Hospital, Shanghai, P.R.China
,
Zhangli CuiDepartment of Oncology, Shanghai Yangpu District Shidong Hospital, Shanghai, P.R.China
&
Yuqing DuDepartment of Oncology, Shanghai Yangpu District Shidong Hospital, Shanghai, P.R.ChinaCorrespondence[email protected]
 show all
Pages 1091-1096 | Received 04 Mar 2019, Accepted 13 Mar 2019, Published online: 16 Apr 2019

References

  • Bauer DE, Mitchell CM, Strait KM, Lathan CS, Stelow EB, Luer SC, Muhammed S, Evans AG, Sholl LM, Rosai J, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res. 2012;18(20):5773–5779. doi:10.1158/1078-0432.
  • Polsani A, Braithwaite KA, Alazraki AL, Abramowsky C, Shehata BM. 2012. NUT midline carcinoma: an imaging case series and review of literature. Pediatr Radiol. 42(2):205–210. doi:10.1007/s00247-011-2272-3.
  • French CA, Kutok JL, Faquin WC, Toretsky JA, Antonescu CR, Griffin CA, Nose V, Vargas SO, Moschovi M, Tzortzatou-Stathopoulou F, et al. Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol. 2004;22(20):4135–4139. doi:10.1200/JCO.2004.02.107.
  • Haack H, Johnson LA, Fry CJ, Crosby K, Polakiewicz RD, Stelow EB, Hong SM, Schwartz BE, Cameron MJ, Rubin MA, et al. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol. 2009;33(7):984–991. doi:10.1097/PAS.0b013e318198d666.
  • Bishop JA, French CA, Ali SZ. 2016. Cytopathologic features of NUT midline carcinoma: A series of 26 specimens from 13 patients. Cancer Cytopathol. 124(12):901–908. doi:10.1002/cncy.21761.
  • French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol. 2012;7:247–265. doi:10.1146/annurev-pathol-011811-132438.
  • Chau NG, Hurwitz S, Mitchell CM, Aserlind A, Grunfeld N, Kaplan L, Hsi P, Bauer DE, Lathan CS, Rodriguez-Galindo C, et al. Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. Cancer. 2016;122(23):3632–3640. doi:10.1146/annurev-pathol-011811-132438.
  • Den Bakker MA, Beverloo BH, van Den Heuvel-Eibrink MM, Meeuwis CA, Tan LM, Johnson LA, French CA, van Leenders GJ. 2009. NUT midline carcinoma of the parotid gland with mesenchymal differentiation. Am J Surg Pathol. 33(8):1253–1258. doi:10.1146/annurev-pathol-011811-132438.
  • Ziai J, French CA, Zambrano E. 2010. NUT gene rearrangement in a poorly-differentiated carcinoma of the submandibular gland. Head Neck Pathol. 4(2):163–168. doi:10.1146/annurev-pathol-011811-132438.
  • Shehata BM, Steelman CK, Abramowsky CR, Olson TA, French CA, Saxe DF, Ricketts RR, Katzenstein HM. 2010. NUT midline carcinoma in a newborn with multiorgan disseminated tumor and a 2-year-old with a pancreatic/hepatic primary. Pediatr Dev Pathol. 13(6):481–485. doi:10.2350/09-10-0727-CR.1.
  • Mertens F, Wiebe T, Adlercreutz C, Mandahl N, French CA. 2007. Successful treatment of a child with t(15;19)-positive tumor. Pediatr Blood Cancer. 49(7):1015–1017. doi:10.1002/pbc.20755.
  • Lemelle L, Pierron G, Freneaux P, Huybrechts S, Spiegel A, Plantaz D, Julieron M, Dumoucel S, Italiano A, Millot F, et al. NUT carcinoma in children and adults: A multicenter retrospective study. Pediatr Blood Cancer. 2017;64:12. doi:10.1002/pbc.26693.
  • Mirguet O, Gosmini R, Toum J, Clement Ca, Barnathan M, Brusq Jm, Mordaunt Je, Grimes Rm, Crowe M, Pineau O et al. Discovery of epigenetic regulator I-BET762: Lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. J Med Chem. 2013;56(19):7501–7515. doi:10.1021/jm401088k.
  • Schwartz BE, Hofer MD, Lemieux ME, Bauer DE, Cameron MJ, West NH, Agoston ES, Reynoird N, Khochbin S, Ince TA, et al. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res. 2011;71(7):2686–2696. doi:10.1158/0008-5472.CAN-10-3513.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.